

Title: Real-world characteristics and treatment patterns of calcitonin gene-related peptide monoclonal antibody users: A Japanese claims database-based study

Authors: Tsubasa Takizawa,¹ Ryo Takemura,² Kaname Ueda,³ Yasuhiro Miki,³ Chie Hashimoto,³

Affiliations:

¹ Department of Neurology, Keio University School of Medicine, Tokyo, Japan;

² Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan;

³ Eli Lilly Japan K.K., Kobe, Japan.

Corresponding author:

Kaname Ueda, Japan Value Evidence and Outcomes,

Eli Lilly Japan K.K.

5-1-28 Isogami-dori, Chuo-ku,

Kobe 651-0086,

Japan.

E-mail: ueda_kaname@lilly.com

Phone: +81-78-242-9519

Table S1: Definitions of the terminology

Term	Definition
Baseline period	12 months before the index date
Index date	Date of the first CGRP mAb prescription
Index CGRP mAb treatment period	From index date to the end of the CGRP mAb treatment (defined as ≥ 90 -day gap between prescriptions) or end of study period)
Post-index CGRP mAb treatment period	Up to 6 months after the end of the index CGRP mAb treatment or end of the study period

Table S2: ICD-10 codes for baseline comorbidities

Comorbidity	ICD-10 code
Cerebrovascular disease	I60-I69
Hypertension	I10-I16
Ischemic heart disease	I20-I25
Arrhythmia	I49.9
Autoimmune disorders	D89.9
Restless leg syndrome	G25.8
Meniere's disease	H81.0
Endometriosis	N80
Irritable bowel syndrome	K58
Biliary tract disease	K83.9
Calculus of kidney and uterus	N20
Glaucoma	H40
Dry eye	H04.1
Chronic fatigue syndrome	R53
Fibromyalgia	M79.7
Peripheral vascular disease	I73.9
Malignant neoplasm of brain	C71.9
Malignant neoplasm (except brain)	C71.0
Meningitis	G03.9
Mood (affective) disorders	F30-F39
Neurotic, stress-related, and somatoform disorders	F40-F48
Epilepsy	G40
Thyroid gland disorders	E07.9
Diabetes mellitus	E08-E13
Non-migraine headache	R51, G44.1-G44.4, G44.8, G44.9
Cluster headache	G44.1
Tension type headache	G44
Medication overuse headache	G44.4
Sleep disorders	G47
Mitral valve prolapse	I34.1
Neuropathy	G57-G59
Neuralgia	M79.2, G50.0, G52.1
Constipation	K59 and/or a prescription of treatment for constipation (ATC code A06)

Abbreviation: ICD-10 – International Classification of Diseases, 10th Revision

Table S3: ATC codes/drug names for prescribed acute or preventive migraine medications

Prescribed acute medications	ATC code or drug name
Acetaminophen	N02BE01
NSAIDs	M02A, N02B
Triptan	N02CC01
Lasmiditan	N02CC08
Antiemetics	A04
Oral preventive medications	
Antiepileptics	Sodium valproate
Antidepressants	Amitriptyline
Calcium-channel blockers	Lomerizine
β-blockers	Propranolol
CGRP mAbs	
Erenumab	N02CD01
Galcanezumab	N02CD02
Fremanezumab	N02CD03

Abbreviations: ATC – Anatomical Therapeutic Chemical Classification, CGRP mAb – Calcitonin Gene-related Peptide Monoclonal Antibody, NSAID – Non-steroidal Anti-inflammatory Drug

Figure S1: Treatments administered in the baseline period and the first treatment in the post-index galcanezumab treatment period

In the baseline period, no medication is defined as no prescribed medication. **Abbreviations:** SOC – Standard-of-Care




Figure S2: Direct costs of the subgroup of galcanezumab users

Panel a – average monthly migraine-related costs of galcanezumab users and panel b – average monthly non-CGRP mAb migraine-related costs of galcanezumab users. The numbers within each box plot indicate the median cost. The table indicates the equivalent USD value of the costs in JPY considering USD 1 = JPY 127.2.

Abbreviations: CGRP mAb – Calcitonin Gene-related Peptide Monoclonal Antibody, JPY – Japanese Yen

